TRP Channels and Piezo Mechanosensors in ME/CFS Pathophysiology
This section covers the foundational mechanosensation and nociception literature underpinning the TRP channel and Piezo channel hypotheses in ME/CFS. Papers here establish: (1) reduced RBC deformability in ME/CFS (Saha 2019); (2) Piezo1 as RBC volume regulator via Gardos channel (Cahalan 2015); (3) Piezo2 as mediator of tactile allodynia and proprioception (Szczot 2018); (4) multiple chemical sensitivity (MCS) as TRP-sensitization syndrome (Molot 2023); (5) prostaglandin-TRPV1 sensitization loop (Moriyama 2005); (6) TRPV1-COX2 feed-forward amplification (Li 2021); (7) TRPV1-mast cell degranulation axis (Costa/Souza 2024); (8) TRPA1 as oxidative stress sensor via cysteine modification (Macpherson 2007).
1 Saha et al. 2019 β RBC Deformability Diminished in ME/CFS
Full Citation:: Saha AK, Schmidt BR, Wilhelmy J, et al. Red blood cell deformability is diminished in patients with chronic fatigue syndrome. Clinical Hemorheology and Microcirculation. 2019;71(1):113β116. DOI:: 10.3233/CH-180469 Published:: 2019 Study Design:: Case-control, ektacytometry of RBCs from ME/CFS patients vs. healthy controls Key Findings::
- RBC deformability significantly reduced in ME/CFS patients compared to healthy controls
- Reduced deformability implies impaired passage through narrow capillaries, potentially reducing oxygen delivery
- Authors propose hemorheological abnormality as contributor to exercise intolerance and post-exertional fatigue
- Ronald W.\ Davis group (Stanford)Conclusion:: ME/CFS patients have measurably stiffer red blood cells, consistent with impaired microcirculatory oxygen delivery and a Piezo1 dysregulation hypothesis. Limitations:: Small sample; does not establish Piezo1 as mechanism; cross-sectional; no exercise challenge data. Certainty Assessment::
- *Sample size:* n=29 ME/CFS, n=29 controls
- *Design:* Case-control, ektacytometry
- *Replication:* Not yet independently replicated; single brief communication
- *Score:* 0.452 Cahalan et al. 2015 β Piezo1 Links Mechanical Forces to RBC Volume
Full Citation:: Cahalan SM, Lukacs V, Ranade SS, Chien S, Bandell M, Patapoutian A. Piezo1 links mechanical forces to red blood cell volume. eLife. 2015;4:e07370. DOI:: 10.7554/eLife.07370 Published:: 2015 Study Design:: Conditional knockout mouse model; electrophysiology; osmotic fragility assays Key Findings::
- Piezo1 conditional knockout in RBCs produces overhydrated, mechanically fragile erythrocytes
- Piezo1 regulates RBC volume via calcium influx activating KCa3.1 (Gardos) channel, causing K^+^ efflux and cell dehydration
- Establishes Piezo1 as essential volume homeostasis channel in RBCs
- Patapoutian group (Nobel Prize 2021); foundational Piezo1 RBC paperConclusion:: Piezo1 is the primary mechanical sensor governing RBC volume; its dysregulation can produce stiffened or fragile RBCs with impaired deformability. Limitations:: Mouse model; does not directly address ME/CFS; human Piezo1 gain-of-function variants (hereditary xerocytosis) provide supporting but distinct human evidence. Certainty Assessment::
- *Sample size:* Conditional knockout mouse; multiple cohorts
- *Design:* Mechanistic mouse genetics + electrophysiology
- *Replication:* Fully replicated; foundational finding; confirmed by multiple groups
- *Score:* 0.853 Szczot et al. 2018 β Piezo2 Mediates Injury-Induced Tactile Pain in Mice and Humans
Full Citation:: Szczot M, Liljencrantz J, Ghitani N, et al. PIEZO2 mediates injury-induced tactile pain in mice and humans. Science Translational Medicine. 2018;10(462):eaat9892. DOI:: 10.1126/scitranslmed.aat9892 Published:: October 2018 Study Design:: Combination of Piezo2-deficient human patients (loss-of-function) and conditional Piezo2 knockout mice; quantitative sensory testing Key Findings::
- Piezo2 loss-of-function in humans causes profound proprioceptive ataxia and absence of tactile allodynia after injury
- Piezo2 conditional knockout mice do not develop mechanical allodynia post-injury, unlike wild-type
- Confirms Piezo2 as the primary mechanotransducer for light touch, proprioception, and injury-induced tactile hypersensitivity
- Piezo2 gain-of-function (Piezo2-CRAMPED syndrome): joint hypermobility, allodynia, progressive scoliosis --- features overlapping with hEDSConclusion:: Piezo2 is required for mechanical allodynia; loss prevents tactile pain hypersensitivity while gain produces hypermobility-allodynia phenotype resembling hEDS/ME-CFS comorbidity pattern. Limitations:: Human loss-of-function subjects are rare; gain-of-function syndrome (CRAMPED) not yet studied in ME/CFS cohorts; direct ME/CFS Piezo2 function data absent. Certainty Assessment::
- *Sample size:* Small number of human Piezo2-deficient patients + mouse model
- *Design:* Human genetics + conditional knockout + quantitative sensory testing
- *Replication:* Partially replicated; Piezo2 proprioception role confirmed by multiple groups
- *Score:* 0.804 Molot et al. 2023 β Multiple Chemical Sensitivity: Time to Catch Up to the Science
Full Citation:: Molot J, Sears M, Anisman H. Multiple chemical sensitivity: Itβs time to catch up to the science. Neuroscience and Biobehavioral Reviews. 2023;151:105227. DOI:: 10.1016/j.neubiorev.2023.105227 Published:: 2023 Study Design:: Comprehensive narrative review with mechanistic synthesis Key Findings::
- Multiple chemical sensitivity (MCS) is mediated by sensitization of TRPV1 and TRPA1
- Prior inflammation, oxidative stress, or infection lowers TRP activation threshold below ordinary chemical concentrations
- Fragrances activate TRPA1 (allyl isothiocyanate-like structures); capsaicin-analogues activate TRPV1 --- both at sub-threshold concentrations in sensitized patients
- Capsaicin challenge studies in MCS patients demonstrate TRPV1 sensitization measurably
- MCS co-occurs with ME/CFS, fibromyalgia, and MCAS at high rates; shared TRP sensitization mechanism proposed as common pathwayConclusion:: MCS is not a psychiatric disorder but a neurobiological sensitization syndrome mediated by TRP channels; overlapping prevalence with ME/CFS supports shared pathophysiology. Limitations:: Review; underlying MCS clinical studies often have small samples; no direct TRP measurement in ME/CFS patients yet. Certainty Assessment::
- *Sample size:* Review; underlying studies vary (n=20--150)
- *Design:* Narrative review; mechanistic synthesis
- *Replication:* MCS-TRP link: partially replicated; ME/CFS-specific data absent
- *Score:* 0.655 Moriyama et al. 2005 β Sensitization of TRPV1 by EP1 and IP Prostaglandin Receptors
Full Citation:: Moriyama T, Higashi T, Togashi K, Iida T, Segi E, Sugimoto Y, Tominaga T, Narumiya S, Tominaga M. Sensitization of TRPV1 by EP1 and IP reveals peripheral nociceptive mechanism of prostaglandins. Molecular Pain. 2005;1:3. DOI:: 10.1186/1744-8069-1-3 Published:: January 2005 Study Design:: In vitro electrophysiology (DRG neurons) + in vivo mouse behavioral assays Key Findings::
- PGE~2~ and PGI~2~ sensitize TRPV1 via EP1 and IP G-protein coupled receptors
- Sensitization lowers TRPV1 thermal threshold and increases capsaicin sensitivity
- Both protein kinase A (PKA) and protein kinase C (PKC) pathways involved in TRPV1 phosphorylation/sensitization
- Establishes molecular mechanism for prostaglandin-mediated peripheral nociceptor sensitizationConclusion:: Prostaglandins sensitize TRPV1 via EP1/IP receptors, explaining why anti-inflammatory drugs (NSAIDs reducing prostaglandins) can reduce thermal hyperalgesia. Limitations:: In vitro primary DRG neurons; older study (2005); human translation implied but not directly demonstrated. Certainty Assessment::
- *Sample size:* In vitro DRG + mouse in vivo; multiple experiments
- *Design:* Mechanistic electrophysiology + mouse behavioral
- *Replication:* Fully replicated; foundational mechanism, confirmed in hundreds of subsequent papers
- *Score:* 0.756 Li et al. 2021 β TRPV1 Feed-Forward Sensitization via COX2 Upregulation
Full Citation:: Li T, Wang G, Hui VCC, Saad D, de Sousa Valente J, La Montanara P, Nagy I. TRPV1 feed-forward sensitization depends on COX2 upregulation in primary sensory neurons. Scientific Reports. 2021;11(1):3514. DOI:: 10.1038/s41598-021-82829-6 Published:: February 2021 Study Design:: In vitro primary sensory neuron cultures; COX2 inhibitors; RT-PCR and calcium imaging Key Findings::
- TRPV1 activation induces COX2 (cyclooxygenase-2) upregulation in sensory neurons within ~30 minutes
- COX2-derived prostaglandins re-sensitize TRPV1 via EP receptors, creating a feed-forward amplification loop
- Loop can be broken by COX2 inhibitors (NSAIDs) or TRPV1 antagonists
- Demonstrates TRPV1 is both sensor and amplifier in nociceptive sensitizationConclusion:: TRPV1 activation creates its own amplification through COX2-prostaglandin signaling; this loop explains persistent hypersensitivity after initial nociceptive triggers. Limitations:: In vitro only; human primary sensory neuron equivalence not directly tested; COX2 induction timing may differ in vivo. Certainty Assessment::
- *Sample size:* In vitro primary sensory neuron cultures
- *Design:* Mechanistic in vitro; pharmacological dissection
- *Replication:* Not yet independently replicated; mechanism internally coherent
- *Score:* 0.707 Costa et al. 2024 β Topiramate Inhibits Capsaicin-Induced Mast Cell Degranulation (cited as Souza2024)
Full Citation:: Costa RF, Rosas EP, Paz ST, de Freitas MFL, de Souza SL, de Andrade JR, de Oliveira DA, Jansen-Olesen I, Christensen SL, Valença MM. Topiramate Inhibits Capsaicin-Induced Mast Cell Degranulation and CGRP Release in Rat Dura Mater. Brain Sciences. 2024;14(11):1070. DOI:: 10.3390/brainsci14111070 Published:: November 2024 Study Design:: Ex vivo rat dura mater preparation; capsaicin TRPV1 agonist stimulation; mast cell degranulation and CGRP measurement Key Findings::
- Capsaicin (TRPV1 agonist) triggers mast cell degranulation and CGRP release in rat dura mater
- Topiramate inhibits both degranulation and CGRP release downstream of TRPV1 activation
- Demonstrates TRPV1-mast cell axis in neurogenic inflammation: TRPV1 activation on sensory fibers triggers adjacent mast cells
- Mechanism is non-IgE pathway (neurogenic, not allergic mast cell activation)Conclusion:: TRPV1 on sensory fibers activates nearby mast cells via non-IgE neurogenic pathway; topiramate may block this axis, relevant to migraine and neuroinflammatory conditions. Limitations:: Animal model (rat); ex vivo preparation; dura mater-specific; direct relevance to ME/CFS MCAS subtype is extrapolated. Certainty Assessment::
- *Sample size:* Rat ex vivo; n not reported for animal cohort
- *Design:* Ex vivo pharmacological; animal model
- *Replication:* Not yet independently replicated; TRPV1-mast cell axis concept supported by other studies
- *Score:* 0.558 Macpherson et al. 2007 β TRPA1 Activated by Covalent Modification of Cysteines
Full Citation:: Macpherson LJ, Dubin AE, Evans MJ, Marr F, Schultz PG, Cravatt BF, Patapoutian A. Noxious compounds activate TRPA1 ion channels through covalent modification of cysteines. Nature. 2007;445:541β545. DOI:: 10.1038/nature05544 Published:: February 2007 Study Design:: In vitro electrophysiology; click-chemistry covalent labeling; mass spectrometry; mutagenesis Key Findings::
- TRPA1 is activated by electrophilic/oxidative compounds (mustard oil, cinnamaldehyde, acrolein, H~2~O~2~) via covalent modification of reactive cysteine residues
- 14 cytosolic cysteine residues identified; 3 are required for normal channel activation
- The 14 ankyrin repeats in the N-terminus contain the key cysteine sensors
- Establishes TRPA1 as a molecular sensor for oxidative stress, tissue damage metabolites, and electrophilic irritants
- Patapoutian group; landmark paper confirming TRPA1's role as ROS/electrophile sensorConclusion:: TRPA1 functions as a chemical/oxidative stress sensor through direct covalent modification of cytosolic cysteines; oxidative stress (ROS) in ME/CFS would activate TRPA1 on nociceptors and Schwann cells. Limitations:: In vitro only; mechanism confirmed in heterologous expression systems and mouse DRG; in vivo relevance and ME/CFS specificity extrapolated. Certainty Assessment::
- *Sample size:* In vitro; mouse DRG; mechanistic
- *Design:* In vitro electrophysiology + biochemistry; landmark Nature paper
- *Replication:* Fully replicated; foundational mechanism; cited thousands of times
- *Score:* 0.8511 Russo et al. 2023 β Ambroxol for Neuropathic Pain: Review of Repurposing Evidence
Full Citation:: Russo MA, Baron R, Dickenson AH, Kern K-U, Santarelli DM. Ambroxol for neuropathic pain: hiding in plain sight? Pain. 2023;164(1):3β13. DOI:: 10.1097/j.pain.0000000000002693 Published:: January 2023 Study Design:: Narrative review; synthesis of preclinical and clinical case series / small trial evidence Key Findings::
- Ambroxol blocks Nav1.8 and Nav1.7 voltage-gated sodium channels in sensory neurons; established mechanism for analgesic activity
- Clinical case series and small uncontrolled studies report pain reduction in trigeminal neuralgia, fibromyalgia, and complex regional pain syndrome
- Long-standing OTC safety profile at mucolytic doses (30--75 mg/day); neuropathic pain doses 75--300 mg/day studied off-label without serious adverse effects reported
- No controlled clinical trials had been completed at time of publication; authors call for formal RCTs
- Bromhexine (prodrug of ambroxol) has equivalent mechanisms; ambroxol is the active metaboliteConclusion:: Ambroxol is an established drug with a good safety record; preclinical and preliminary clinical evidence supports its repurposing for neuropathic pain via sodium channel block, but controlled trials are needed. Limitations:: Review paper; clinical evidence is case series and small studies only (no RCTs at time of publication); doses needed for neuropathic pain exceed standard OTC mucolytic dosing; optimal formulation (topical vs. oral) not established. Certainty Assessment::
- *Sample size:* Review; clinical data from case series (n = 10--50 range in cited studies)
- *Design:* Narrative review in Pain (high-impact journal; peer-reviewed)
- *Replication:* Nav1.8 mechanism well-replicated preclinically; clinical efficacy not yet replicated in RCTs
- *Score:* 0.60